Sansure Biotech, Inc. (688289) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sansure Biotech, Inc.

Why is Sansure Biotech, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of -21.62% and Operating profit at -51.32% over the last 5 years

The company has declared Negative results for the last 10 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at CNY 187.18 MM
DEBT-EQUITY RATIO (HY) Highest at -40.6 %
INTEREST(Q) Highest at CNY 6.13 MM

With ROE of 2.60%, it has a very attractive valuation with a 1.64 Price to Book Value

Over the past year, while the stock has generated a return of -15.24%, its profits have fallen by -49.9%
At the current price, the company has a high dividend yield of 2.7

Below par performance in long term as well as near term

Along with generating -15.24% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sansure Biotech, Inc. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sansure Biotech, Inc.

-29.27%

-0.04

31.79%

China Shanghai Composite

8.25%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-16.49%

EBIT Growth (5y)

-49.15%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.50

Sales to Capital Employed (avg)

0.18

Tax Ratio

6.85%

Dividend Payout Ratio

151.11%

Pledged Shares

Institutional Holding

ROCE (avg)

41.67%

ROE (avg)

18.63%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

113

Industry P/E

Price to Book Value

1.14

EV to EBIT

68.30

EV to EBITDA

21.26

EV to Capital Employed

1.23

EV to Sales

3.40

PEG Ratio

Dividend Yield

3.76%

ROCE (Latest)

1.80%

ROE (Latest)

1.01%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -7.35% (YoY

-36What is not working for the Company

INTEREST COVERAGE RATIO(Q)

Lowest at 744.92

ROCE(HY)

Lowest at 2.16%

DEBT-EQUITY RATIO (HY)

Highest at -37.96 %

OPERATING PROFIT(Q)

Lowest at CNY 49.12 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 11.23 %

PRE-TAX PROFIT(Q)

At CNY 57.86 MM has Fallen at -48.34%

NET PROFIT(Q)

At CNY 49.22 MM has Fallen at -45.77%

CASH AND EQV(HY)

Lowest at CNY 8,048.39 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.87 times

INTEREST(Q)

Highest at CNY 6.59 MM

Here's what is working for Sansure Biotech, Inc.

Raw Material Cost

Fallen by -7.35% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sansure Biotech, Inc.

Interest Coverage Ratio

Lowest at 744.92 and Fallen

In each period in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest

At CNY 6.59 MM has Grown at 15.24%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Profit

Lowest at CNY 49.12 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 11.23 % and Fallen

In each period in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

At CNY 57.86 MM has Fallen at -48.34%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 49.22 MM has Fallen at -45.77%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Debt-Equity Ratio

Highest at -37.96 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Interest

Highest at CNY 6.59 MM

in the last five periods and Increased by 15.24% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Cash and Eqv

Lowest at CNY 8,048.39 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 0.87 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio